<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02013245</url>
  </required_header>
  <id_info>
    <org_study_id>MTBVAC-01</org_study_id>
    <nct_id>NCT02013245</nct_id>
  </id_info>
  <brief_title>Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine.</brief_title>
  <acronym>MTBVAC</acronym>
  <official_title>Phase I Double Blind, Randomized, Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC in Comparison With BCG in Elispot TB(ESAT-6, CFP10, PPD)- and HIV- Negative Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biofabri, S.L</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad de Zaragoza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TuBerculosis Vaccine Initiative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biofabri, S.L</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and immunogenicity of MTBVAC as a potential
      substitute for BCG vaccination. BCG vaccination has indeed demonstrated its major limitation
      in inducing protection against tuberculosis (TB). Novel vaccines are essential to fight
      against the current world epidemics in tuberculosis and resistance to anti-TB drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, controlled Phase I study conducted at CHUV, Lausanne,
      Switzerland, to compare MTBVAC to licensed BCG in healthy, PPD-negative adult male and female
      volunteers. The study involves random allocation of up to 36 subjects (4 vaccine groups of 9
      volunteers fulfilling the inclusion criteria) to MTBVAC (tested at three separate doses) or
      standard dose BCG (on a 3 verum : 1control basis) in a dose-escalation manner to one of three
      cohorts. Each cohort includes 9 subjects set to receive MTBVAC lowest dose 5x10E03, or MTBVAC
      intermediate dose 5x10E04, or high dose 5x10E05 colony forming units (CFU) in 0.1 mL and 3
      subjects set to receive standard dose BCG (5x10E05 CFU in 0.1 mL). A single intradermal
      injection is given in the non-dominant arm of each volunteer starting with the lowest MTBVAC
      dose. Each MTBVAC vaccine dose is administered staggered by cohort, starting with the cohort
      with the lowest MTBVAC dose level. After at least 35 days of follow-up within each cohort a
      safety review and evaluation by Independent Data Safety Monitoring Board provides go/no-go
      for vaccination of the subsequent cohorts if no safety issues as defined by preset stopping
      rules.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events up to 210 Days After Vaccination</measure>
    <time_frame>7 months follow up</time_frame>
    <description>Safety and reactogenicity for all subjects as determined by:
Occurrence of solicited symptoms during the 7-day follow-up period following vaccination and occurrence of unsolicited symptoms during the 210-day follow-up period following vaccination.
Occurrence of grade 3 vaccine related local and general symptoms during the 210-day follow-up period following vaccination and occurrence of serious adverse events throughout the entire study period.
Haematological and biochemical safety test levels prior and after vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Three-cytokine-positive CD4+ T-cell Response</measure>
    <time_frame>Day 28</time_frame>
    <description>Measure of the kinetics of CD4+ T-cell responses to MTBVAC or BCG vaccination by tracking the expression of IFNγ, TNFα and IL-2 upon stimulation with live MTBVAC or BCG</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Tuberculosis</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>MTBVAC group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: MTBVAC live vaccine (low dose 5 x 10E03 CFU/0.1mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MTBVAC Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: MTBVAC live vaccine (middle dose 5 x 10E04 CFU/0.1mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MTBVAC Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: MTBVAC live vaccine (high dose 5 x 10E05 CFU/0.1mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCG Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Commercially available BCG live vaccine (dose 5 x 10E05 CFU/0.1mL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MTBVAC live vaccine</intervention_name>
    <description>Live-attenuated Mycobacterium tuberculosis vaccine</description>
    <arm_group_label>MTBVAC group 1</arm_group_label>
    <arm_group_label>MTBVAC Group 2</arm_group_label>
    <arm_group_label>MTBVAC Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Commercially available BCG live vaccine</intervention_name>
    <description>Live-attenuated Mycobacterium bovis vaccine</description>
    <arm_group_label>BCG Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the Investigator believes that they can and will comply with the
             requirements of the protocol

          -  Subjects who have no evidence of exposition to BCG as demonstrated by a ELISPOT PPD
             assay along with no history of BCG vaccination and no BCG scar

          -  A male or female between, and including, 18 and 45 years of age at the time of the
             vaccination.

          -  Written informed consent obtained from the subject prior to any study procedure.

          -  If the subject is female, she must be of non-childbearing potential, or if she is of
             childbearing potential, she must practice adequate contraception

          -  Clinically acceptable laboratory values for blood tests.

          -  Seronegative for human immunodeficiency virus 1 and -2 (HIV-1/2) antibodies, p24
             antigen, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibodies.

          -  No evidence of pulmonary pathology as confirmed by chest X-ray.

          -  No history of extrapulmonary TB.

          -  No history of previous contact with M. tuberculosis (latent tuberculosis) as
             demonstrated by a negative ELISPOT Tb (ESAT-6, CFP10) assay.

        Exclusion Criteria:

          -  History of allergic reactions (significant IgE-mediated events) or anaphylaxis to
             previous immunisations (any vaccine).

          -  History of allergic disease or reactions

          -  History of previous administration of experimental Mycobacterium tuberculosis
             vaccines.

          -  Use of any investigational or non-registered product (drug or vaccine) in another
             experimental protocol other than the study vaccines within 30 days preceding the
             vaccination, or planned use during the study period.

          -  Any chronic drug therapy to be continued during the study period.

          -  Chronic administration of immunosuppressors or other immune-modifying drugs.

          -  Administration of any immunoglobulins, any immunotherapy and/or any blood products
             within the three months preceding the vaccination, or planned administrations during
             the study period.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition (including
             HIV) based on medical history and physical examination.

          -  Any condition or history of any acute or chronic illness or medication which, in the
             opinion of the Investigator, may interfere with the evaluation of the study
             objectives.

          -  A family history of congenital or hereditary immunodeficiency.

          -  A stay of more than 2 months in a highly endemic area (e.g. Eastern Europe (Romania,
             Bulgaria) and low-income countries) within 6 months prior to the screening visit or
             travel of more than 2 months foreseen in an area of high endemicity after the
             enrolment into the study.

          -  History of any neurologic disorders or seizures.

          -  History of chronic alcohol consumption and/or drug abuse.

          -  Major congenital defects.

          -  Pregnant or lactating female.

          -  Female planning to become pregnant or planning to discontinue contraceptive
             precautions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Spertini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <state>Canton of Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Arbues A, Aguilo JI, Gonzalo-Asensio J, Marinova D, Uranga S, Puentes E, Fernandez C, Parra A, Cardona PJ, Vilaplana C, Ausina V, Williams A, Clark S, Malaga W, Guilhot C, Gicquel B, Martin C. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine. 2013 Oct 1;31(42):4867-73. doi: 10.1016/j.vaccine.2013.07.051. Epub 2013 Aug 17.</citation>
    <PMID>23965219</PMID>
  </reference>
  <reference>
    <citation>Verreck FA, Vervenne RA, Kondova I, van Kralingen KW, Remarque EJ, Braskamp G, van der Werff NM, Kersbergen A, Ottenhoff TH, Heidt PJ, Gilbert SC, Gicquel B, Hill AV, Martin C, McShane H, Thomas AW. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One. 2009;4(4):e5264. doi: 10.1371/journal.pone.0005264. Epub 2009 Apr 15. Erratum in: PLoS One. 2011;6(2). doi:10.1371/annotation/e599dafd-8208-4655-a792-21cb125f7f66.</citation>
    <PMID>19367339</PMID>
  </reference>
  <reference>
    <citation>Gonzalo-Asensio J, Mostowy S, Harders-Westerveen J, Huygen K, Hernández-Pando R, Thole J, Behr M, Gicquel B, Martín C. PhoP: a missing piece in the intricate puzzle of Mycobacterium tuberculosis virulence. PLoS One. 2008;3(10):e3496. doi: 10.1371/journal.pone.0003496. Epub 2008 Oct 23.</citation>
    <PMID>18946503</PMID>
  </reference>
  <reference>
    <citation>Martin C, Williams A, Hernandez-Pando R, Cardona PJ, Gormley E, Bordat Y, Soto CY, Clark SO, Hatch GJ, Aguilar D, Ausina V, Gicquel B. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine. 2006 Apr 24;24(17):3408-19.</citation>
    <PMID>16564606</PMID>
  </reference>
  <reference>
    <citation>Pérez E, Samper S, Bordas Y, Guilhot C, Gicquel B, Martín C. An essential role for phoP in Mycobacterium tuberculosis virulence. Mol Microbiol. 2001 Jul;41(1):179-87.</citation>
    <PMID>11454210</PMID>
  </reference>
  <results_reference>
    <citation>Spertini F, Audran R, Chakour R, Karoui O, Steiner-Monard V, Thierry AC, Mayor CE, Rettby N, Jaton K, Vallotton L, Lazor-Blanchet C, Doce J, Puentes E, Marinova D, Aguilo N, Martin C. Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. Lancet Respir Med. 2015 Dec;3(12):953-62. doi: 10.1016/S2213-2600(15)00435-X. Epub 2015 Nov 17.</citation>
    <PMID>26598141</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2013</study_first_submitted>
  <study_first_submitted_qc>December 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2013</study_first_posted>
  <results_first_submitted>March 15, 2016</results_first_submitted>
  <results_first_submitted_qc>February 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 24, 2017</results_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MTBVAC Group 1</title>
          <description>Intervention: MTBVAC live vaccine (low dose 5 x 10^3 CFU)</description>
        </group>
        <group group_id="P2">
          <title>MTBVAC Group 2</title>
          <description>Intervention: MTBVAC live vaccine (middle dose 5 x 10^4 CFU)</description>
        </group>
        <group group_id="P3">
          <title>MTBVAC Group 3</title>
          <description>Intervention: MTBVAC live vaccine (high dose 5 x 10^5 CFU)</description>
        </group>
        <group group_id="P4">
          <title>BCG Control Group</title>
          <description>Intervention: Commercially available BCG live vaccine (dose 5 x 10^5 CFU)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>MTBVAC low dose group (5 x 10^3 CFU MTBVAC)</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>MTBVAC intermediate dose group (5 x 10^4 CFU MTBVAC)</description>
        </group>
        <group group_id="B3">
          <title>Group 3</title>
          <description>MTBVAC high dose group (5 x 10^5 CFU MTBVAC)</description>
        </group>
        <group group_id="B4">
          <title>BCG Control Group</title>
          <description>BCG standard dose group (5 x 10^5 CFU BCG)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="9.6"/>
                    <measurement group_id="B2" value="28.2" spread="3.2"/>
                    <measurement group_id="B3" value="27.1" spread="6.1"/>
                    <measurement group_id="B4" value="25.6" spread="3.4"/>
                    <measurement group_id="B5" value="27.2" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events up to 210 Days After Vaccination</title>
        <description>Safety and reactogenicity for all subjects as determined by:
Occurrence of solicited symptoms during the 7-day follow-up period following vaccination and occurrence of unsolicited symptoms during the 210-day follow-up period following vaccination.
Occurrence of grade 3 vaccine related local and general symptoms during the 210-day follow-up period following vaccination and occurrence of serious adverse events throughout the entire study period.
Haematological and biochemical safety test levels prior and after vaccination</description>
        <time_frame>7 months follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MTBVAC Group 1</title>
            <description>Intervention: MTBVAC live vaccine (low dose 5 x 10^3 CFU)</description>
          </group>
          <group group_id="O2">
            <title>MTBVAC Group 2</title>
            <description>Intervention: MTBVAC live vaccine (middle dose 5 x 10^4 CFU)</description>
          </group>
          <group group_id="O3">
            <title>MTBVAC Group 3</title>
            <description>Intervention: MTBVAC live vaccine (high dose 5 x 10^5 CFU)</description>
          </group>
          <group group_id="O4">
            <title>BCG Control Group</title>
            <description>Intervention: Commercially available BCg live vaccine (standard dose 5 x 10^5 CFU)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events up to 210 Days After Vaccination</title>
          <description>Safety and reactogenicity for all subjects as determined by:
Occurrence of solicited symptoms during the 7-day follow-up period following vaccination and occurrence of unsolicited symptoms during the 210-day follow-up period following vaccination.
Occurrence of grade 3 vaccine related local and general symptoms during the 210-day follow-up period following vaccination and occurrence of serious adverse events throughout the entire study period.
Haematological and biochemical safety test levels prior and after vaccination</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Three-cytokine-positive CD4+ T-cell Response</title>
        <description>Measure of the kinetics of CD4+ T-cell responses to MTBVAC or BCG vaccination by tracking the expression of IFNγ, TNFα and IL-2 upon stimulation with live MTBVAC or BCG</description>
        <time_frame>Day 28</time_frame>
        <population>Number of Participants with Three-cytokine-positive CD4+ T-cell Response (per protocol analysis)</population>
        <group_list>
          <group group_id="O1">
            <title>MTBVAC Group 1</title>
            <description>Intervention: MTBVAC live vaccine (low dose 5 x 10^3 CFU)</description>
          </group>
          <group group_id="O2">
            <title>MTBVAC Group 2</title>
            <description>Intervention: MTBVAC live vaccine (middle dose 5 x 10^4 CFU)</description>
          </group>
          <group group_id="O3">
            <title>MTBVAC Group 3</title>
            <description>Intervention: MTBVAC live vaccine (high dose 5 x 10^5 CFU)</description>
          </group>
          <group group_id="O4">
            <title>BCG Control Group</title>
            <description>Intervention: Commercially available BCg live vaccine (standard dose 5 x 10^5 CFU)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Three-cytokine-positive CD4+ T-cell Response</title>
          <description>Measure of the kinetics of CD4+ T-cell responses to MTBVAC or BCG vaccination by tracking the expression of IFNγ, TNFα and IL-2 upon stimulation with live MTBVAC or BCG</description>
          <population>Number of Participants with Three-cytokine-positive CD4+ T-cell Response (per protocol analysis)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited local and systemic adverse events: within 7 days of vaccination (diary card). Unsolicited local and systemic adverse events at days 0, 7, 28, 56, 90, 150 and 210</time_frame>
      <desc>Safety was assessed based on a collection of solicited local (injection site pain, erythema, induration, pruritus and discharges) and systemic (fever, headache, fatigue, musculoskeletal pains, gastrointestinal symptoms) adverse events (AEs) within 7 days of vaccination (diary card). Unsolicited local and systemic AEs as well as serious AEs (SAEs) were collected during the entire study period.</desc>
      <group_list>
        <group group_id="E1">
          <title>MTBVAC Group 1</title>
          <description>Intervention: MTBVAC live vaccine (low dose 5 x 10^3 CFU)</description>
        </group>
        <group group_id="E2">
          <title>MTBVAC Group 2</title>
          <description>Intervention: MTBVAC live vaccine (middle dose 5 x 10^4 CFU)</description>
        </group>
        <group group_id="E3">
          <title>MTBVAC Group 3</title>
          <description>Intervention: MTBVAC live vaccine (high dose 5 x 10^5 CFU)</description>
        </group>
        <group group_id="E4">
          <title>BCG Control Group</title>
          <description>Intervention: Commercially available BCG live vaccine (standard dose 5 x 10^5 CFU)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Digestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>General headache related or unrelated to vaccination</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <description>Musculoskeletal pain</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain at injection site</sub_title>
                <description>Pain at injection site</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <description>Erythema at injection site</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <description>Induration at injection site</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <description>Pruritis at site of injection</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Discharge</sub_title>
                <description>Discharge from site of injection</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is a first-in-human Phase 1 trial designed to evaluate the safety and tolerability profile of MTBVAC in comparison to BCG.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. François Spertini, Associate Professor, Division Immunology &amp; Allergy</name_or_title>
      <organization>Centre Hospitalier Universitaire Vaudois (CHUV)</organization>
      <phone>+41 21 31 40 799</phone>
      <email>Francois.Spertini@chuv.ch</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

